Sanofi SA (ADR) (NYSE:SNY) To Be On Growth Track By Q4

Posted by Ryan Mandell October 8, 2013 0 Comment 1706 views


Over the past 3 years, Sanofi SA (ADR) (NYSE:SNY) lost patent protection for 9 of its drugs which has definitely been a big blow for the company. But Chris Viehbacher, the company Chief Executive Officer said that he expects the company to be back on the growth-track in the Q4.

The CEO said that the company has just travelled through some of the most focused and deepest patents in the pharma industry and that they are totally focused on the Q4. They are hoping that the company moves back into a healthy position by 2014. In addition, he said that post all the generic competition that emerged for the drugs including all the rivalry for its blood thinner. Sanofi SA (ADR) (NYSE:SNY) has now cut down its full-year earnings projections. The company is at a stage wherein it cannot afford any expiry on the protection on the company’s brand-name drug and is also in efforts to bring in new and innovative drugs into the market.

Monday’s trading session

In Monday’s trading, Sanofi SA (ADR) (NYSE:SNY) rose by 0.14%. The opening price of the shares was $50.57, which climbed to an intraday high of $50.81 and dipped to a close of $50.57. Approximately 0.491 million shares were traded on Monday while an average volume of 2.54 million shares were traded over a 30 day period. The 52-week low of Sanofi SA (ADR) (NYSE:SNY) shares is $42.20 and its 52-week high is $55.94. The company has a market capitalization of $134.73 billion.

About the company

Sanofi SA (ADR) (NYSE:SNY) was previously Sanofi-Aventis. It is a global and a diversified health-care headquartered in France. It is engaged in discovering, developing and distributing therapeutic-solutions that are focused on patients’ needs. It is focused on the healthcare field with 6 growth platforms: 1) diabetes solutions, 2) human vaccines, 3) innovative drugs, 4) consumer healthcare, 5) emerging markets and 6) animal health. It has a portfolio of prescription-drugs, vaccines, consumer healthcare products and other generics products.



About Ryan Mandell

Ryan Mandell is our senior staff writer covering the White House for Political Report, Ryan also coordinates with the main newsroom news items and contributing write-ups on cultural, social and political activities. Ryan holds an undergraduate degree in journalism, a Doctorate in international relations and a Master Degree in mass communications with an emphasis in print journalism. Ryan also covered the International Society of Social Defense congress in Spain in 2007 and taken part in the Global Forum on economic policies

View all post by Ryan Mandell Visit author's website

Write Your Comment